Gastroenterology
Volume 135, Issue 6 , Pages 1953-1960 , December 2008

A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Etanercept in the Treatment of Alcoholic Hepatitis

  • Nicholas C. Boetticher

      Affiliations

    • Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota
    • ,
  • Craig J. Peine

      Affiliations

    • Division of Gastroenterology/Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota
    • ,
  • Paul Kwo

      Affiliations

    • Department of Medicine, Indiana University, Indianapolis, Indiana
    • ,
  • Gary A. Abrams

      Affiliations

    • Alabama Liver & Digestive Specialists, Montgomery, Alabama
    • ,
  • Tushar Patel

      Affiliations

    • Department of Medicine, Scott & White Clinic, Temple, Texas
    • ,
  • Bashar Aqel

      Affiliations

    • Division of Gastroenterology/Department of Medicine, Mayo Clinic, Scottsdale, Arizona
    • ,
  • Lisa Boardman

      Affiliations

    • Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota
    • ,
  • Gregory J. Gores

      Affiliations

    • Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota
    • ,
  • William S. Harmsen

      Affiliations

    • Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota
    • ,
  • Craig J. McClain

      Affiliations

    • Departments of Medicine and Pharmacology & Toxicology, University of Louisville and Louisville VAMC, Louisville, Kentucky
    • ,
  • Patrick S. Kamath

      Affiliations

    • Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota
    • ,
  • Vijay H. Shah

      Affiliations

    • Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota
    • Corresponding Author InformationAddress requests for reprints to: Vijay Shah, MD, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905. fax: (507) 255-6318

Received 28 April 2008 ,Accepted 28 August 2008.

References 

  1. McCullough A, O'Connor J. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2022–2036
  2. Lieber C. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatol. 2000;32:113–128
  3. Menon K, Gores G, Shah V. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc. 2001;76:1021–1029
  4. Baker AL, Jaspan JB, Haines NW, et al. A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology. 1981;80:1410–1414
  5. Halle P, Pare P, Kaptein E, et al. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology. 1982;82:925–931
  6. Akriviadis E, Steindel H, Pinto P, et al. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology. 1990;99:811–818
  7. Morgan TR, Moritz T, Mendenhall C. Nutritional therapy for alcoholic hepatitis (VA Cooperative 275 Study Group). (letter; comment) Gastroenterology. 1992;103:357–359
  8. Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology. 1993;17:564–576
  9. Cabre E, Rodriguez-Iglesias P, Caballeria J, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology. 2000;32:36–42
  10. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637–1648
  11. Morgan T, McClain C. Pentoxifylline and alcoholic hepatitis. Gastroenterology. 2000;119:1787–1791
  12. Mathurin P, Mendenhall C, Carithers R, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo-controlled, double-blind trials of corticosteroids in severe AH. J Hepatol. 2002;36:547–548
  13. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-α monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003;38:419–425
  14. Morgan TR, Weiss DG, Nemchausky B, et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology. 2005;128:882–890
  15. Neuman MG. Cytokines—central factors in alcoholic liver disease. Alcohol Res Health. 2003;27:307–316
  16. Hoek JB, Pastorino JG. Cellular signaling mechanisms in alcohol-induced liver damage. Semin Liver Dis. 2004;24:257–272
  17. Latvala J, Hietala J, Koivisto H, et al. Immune responses to ethanol metabolites and cytokine profiles differentiate alcoholics with or without liver disease. Am J Gastroenterol. 2005;100:1303–1310
  18. McClain C, Barve S, Joshi-Barve S, et al. Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. Alcohol Clin Exp Res. 2005;29:S180–S188
  19. Tilg H, Diehl A. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343:1467–1476
  20. Jalan R, Williams R, Kaser A, et al. Clinical and cytokine response to anti-TNF antibody therapy in severe alcoholic hepatitis. Hepatology. 2001;34:A441
  21. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis (A randomized, controlled trial). Ann Intern Med. 1999;130:478–486
  22. Sandborn W, Hanauer S, Katz S, et al. Etanercept for active Crohn's disease: a randomized double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–1094
  23. ten Cate R, van Suijlekom-Smit L, Brinkman D, et al. Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis. Rheumatology. 2002;41:228–229
  24. Gorman J, Sack K, Davis JJ. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Eng J Med. 2002;346:1349–1356
  25. Steensma D, Mesa R, Li C, et al. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood. 2002;99:2252–2254
  26. Phillips K, Husni M, Karlson E, et al. Experience with etanercept in an academic medical center: are infection rates increased?. Arthritis Rheum. 2002;47:17–21
  27. Menon K, Stadheim L, Kamath P, et al. Safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol. 2004;99:255–260
  28. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. (comment) Hepatology. 2005;41:353–358
  29. Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2001;2:2
  30. Srikureja W, Kyulo NL, Runyon BA, et al. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. (comment) J Hepatol. 2005;42:700–706
  31. Said A, Williams J, Holden J, et al. Model for End-Stage Liver Disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004;40:897–903
  32. Carithers RJ, Herlong H, Diehl A, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis (A randomized multicenter trial). (comments) Ann Intern Med. 1989;110:685–690
  33. Spahr L, Rubbia-Brandt L, Frossard J, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol. 2002;37:448–455
  34. Bird GL, Prach AT, McMahon AD, et al. Randomised controlled double-blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. J Hepatol. 1998;28:194–198
  35. Mato J, Camara J, Fernandez de Paz J, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081–1089
  36. Leist M, Gantner F, Bohlinger I, et al. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am J Pathol. 1995;146:1220–1234
  37. Schafer C, Schips I, Landig J, et al. Tumor-necrosis-factor and interleukin-6 response of peripheral blood monocytes to low concentrations of lipopolysaccharide in patients with alcoholic liver disease. Zeitschrift fur Gastroenterologie. 1995;33:503–508
  38. Lechner AJ, Velasquez A, Knudsen KR, et al. Cholestatic liver injury increases circulating TNF-α and IL-6 and mortality after Escherichia coli endotoxemia. Am J Respir Crit Care Med. 1998;157:1550–1558
  39. Yamada Y, Fausto N. Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor. Am J Pathol. 1998;152:1577–1589
  40. Yin M, Wheeler M, Kono H, et al. Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice. Gastroenterology. 1999;117:942–952
  41. Gallucci R, Simeonova P, Toriumi W, et al. TNF-α regulates TGF α expression in regenerating murine liver and isolated hepatocytes. J Immunol. 2000;164:872–878
  42. Hajeer A, Hutchinson I. TNF-α gene polymorphism: clinical and biological implications. Microsc Res Tech. 2000;50:216–228
  43. Akerman P, Cote P, Yang SQ, et al. Antibodies to tumor necrosis factor-α inhibit liver regeneration after partial hepatectomy. Am J Physiol. 1992;263:G579–G585
  44. Roach D, Bean A, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002;168:4620–4627
  45. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39:1390–1397

 Supported by the NIH (R01 AA013933 to V.S.), the NIH funded Mayo Clinical Research Unit (CTSA), and Amgen (to V.S.), which provided study drug and partially defrayed costs for cytokine analyses that exceeded the NIH budget.

 The authors disclose the following: All analyses and writing were conducted at the Mayo Clinic. Authors have no other conflicts of interest to disclose.

PII: S0016-5085(08)01669-7

doi: 10.1053/j.gastro.2008.08.057

Gastroenterology
Volume 135, Issue 6 , Pages 1953-1960 , December 2008

Article Tools

* Image Usage & Resolution